Many women do not receive guideline-based care for cervical cancer, study finds

NewsGuard 100/100 Score

Women with locally advanced cervical cancer whose treatment follows national guidelines for care have better survival, regardless of race, ethnicity or stage of cancer.

But fewer than three out of five women received guideline-based care. For black and Hispanic women, it's just over half, a new study finds. And that could help explain why cervical cancer outcomes tend to be worse for these women.

Researchers looked at records from 16,195 patients treated between 2004 and 2012 for locally advanced cervical cancer. Patient information was reported to the National Cancer Database, which represents 96 percent of the cervical cancer cases in the United States.

To determine whether patients received care in line with national guidelines, the team looked at who received radiation therapy. National Comprehensive Cancer Network guidelines recommend radiation along with chemotherapy for locally advanced cervical cancer.

Overall, 57 percent of patients received guideline-based care. But those rates varied based on race, from 58 percent in white women to 53 percent in black women and 51 percent in Hispanic women.

What might be most surprising is that a larger gap in guideline-based care was seen among patients treated at centers that saw a large volume of cervical cancer patients, compared to low-volume hospitals.

"It's a common misconception," says study author Shitanshu Uppal, MBBS, assistant professor of obstetrics and gynecology at Michigan Medicine. Research looking at surgical outcomes suggests high-volume centers help reduce disparities. But treatment recommendations don't necessarily improve with practice.

"It's clear that the more surgeries you do, the better you get. But the 'more is better' mantra may not apply to guideline-concordant care," he says. "These are facilities that know what to do and they're doing it. But they're not doing it consistently across all populations."

Over the time period, guideline-based care increased across all populations, but black and Hispanic patients still were less likely than white patients to receive care consistent with guidelines.

"Overall, it's better for everyone. We're closing the gap, but there's still a gap. Even in 2012, we see a 5 percentage-point gap in guideline-based therapy," Uppal says.

The study, published in Obstetrics & Gynecology, did not address reasons why patients might not have received guideline-based care. Cervical cancer tends to be diagnosed in younger women and more often in women facing socioeconomic issues. These factors could influence a patient's likelihood to finish treatment, Uppal suggests. Some patients may refuse certain treatments.

The researchers plan to interview individual patients to better understand the reasons for this disparity, and why there might be barriers to some patients getting treatment.

Not that care will ever be 100 percent aligned with guidelines - there are too many complicated factors for each individual patient. But Uppal expects rates around 75 percent would be a reasonable goal. That's comparable to other types of cancer.

"Understanding the 'why' behind our findings is important - not just for minority populations but for all. We can do better," Uppal says.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy